POSITION: QA DOCUMENT CONTROL Coordinator
Under the supervision of the Manager of RAQA, the Document Control Coordinator is responsible for assigned Quality Documents related to the FDA’s GMP and ISO13485 requirements. These responsibiliti […
B.S./M.S genetics, molecular genetics, molecular biology, biotechnology,. All About Us….
From Illumina, Inc. – 23 Jun 2016 18:25:03 GMT
– View all San Diego jobs
ViaSat is seeking an innovative and exceptionally skilled Director of Talent Acquisition. This person will have global responsibility for identifying, engaging
From ViaSat – 23 Jun 2016 18:13:33 GMT
– View all San Diego jobs
PEAK Technical Staffing is Seeking: Entry Level Lab Tech
Job duties include
? setup, operate and maintain blood gas analyzers.
? Buffer/reagent preparation
? Membrane solution preparation
? Preparing test solutions
? Order and maintain laborato […
Biotech lab and/or Marketing:. Strong attention to detail. Requires 7-10 years’ experience in the Biotech or Cell Biology industry….
From Indeed – 23 Jun 2016 18:03:53 GMT
– View all San Diego jobs
Essential Duties and Responsibilities:
The Lab Assistant will support laboratory staff by maintaining the overall sanitation and organization of the laboratory, while assisting in other tasks as needed. The essential functions include, but are not l […
Maintains and updates a variety of confidential and sensitive electronic and/or hard copy records and/or files….
From General Atomics and Affiliated Companies – 23 Jun 2016 16:08:39 GMT
– View all San Diego jobs
Precision microbiome engineering company to ramp up automation and drug development
SAN FRANCISCO, June 23, 2016 /PRNewswire/ — EpiBiome, a precision microbiome engineering company, today announced it has secured $1 million in debt financing from Silicon Valley Bank (SVB). The financing will allow EpiBiome to ramp up automation and to advance its drug development efforts, as well as purchase additional lab equipment for its new facility.
“SVB has been an incredible strategic partner to us – one that goes beyond the services a traditional bank would provide,” said Dr. Aeron Tynes Hammack, EpiBiome’s co-founder and chief operating officer. “They’ve helped connect us with corporate partners and investors while also producing life sciences reports that perfectly analyze our target markets. These insights and connections have played a significant role in our success.”
This financing announcement follows the January close of EpiBiome’s $6 million Series A funding round. Leading next-generation sequencing investors from the round included Viking Global Investors via Illumina Accelerator Boost Capital, Matrix Capital Management, Alexandria Venture Investments, SV Tech Ventures, China Rock Capital Management and China Ding Cheng Holding Group.
Adding to its accolades and accomplishments, EpiBiome was a graduate from the inaugural class of Illumina Accelerator, the world’s first business accelerator that focuses on helping genomic companies launch.
“We’ve been working with EpiBiome for nearly two years, and it’s our pleasure to continue the partnership,” said Jennifer Friel Goldstein, managing director at Silicon Valley Bank. “Through Illumina Accelerator, we really saw EpiBiome’s potential to dramatically reduce the threat of antibiotic resistance in agriculture. We’re excited to support their continued advancements in tackling infectious diseases through microbiome engineering – which shows beneficial promise to both the agricultural space and human health.”
EpiBiome’s mission is to develop effective, sustainable FDA-approved therapies to combat infectious disease in humans and agriculture without the use of antibiotics. For more information on the microbiome engineering company, visit http://www.epibiome.com.
EpiBiome is a venture-backed precision microbiome engineering company working to curb the growing threat of multi-drug-resistant superbugs by eliminating the use of shared-class antibiotics, those shared between humans and animals, from agriculture.
The company’s management team consists of Nick Conley, PhD (Chief Executive Officer and Co-Founder), Aeron Tynes Hammack, PhD (Chief Operating Officer & Co-Founder), Christina Tsai, PhD (Chief Science Officer & Co-Founder), Lucia Mokres, DVM (Chief Medical Officer), and Bruno Marchon, PhD (Chief Technical Officer). EpiBiome is located at 201 Gateway Blvd., South San Francisco, California 94080. For more information, visit http://www.epibiome.com.
About Silicon Valley Bank
For more than 30 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators. Learn more at svb.com.
Mr. Doyle’s broad strategic management and financing expertise will further contribute to the clinical advancement of LB1148 for the treatment of ileus, adhesions and acute shock
SAN DIEGO, June 23, 2016 /PRNewswire/ — Leading BioSciences Inc., a clinical-stage biopharmaceutical company advancing programs that address medical conditions resulting from a breakdown of the mucosal barrier, today announced that it has appointed Greg Doyle as chief executive officer. Mr. Doyle, a long-standing member of Leading BioSciences’ executive management team and board of directors, previously served as chief operations officer and chief financial officer. He will provide continued leadership and strategic direction to the company’s pipeline development, clinical research and financing activities. Mr. Doyle succeeds Clark Straw, who will remain as chairman of the board.
“Greg has been a cornerstone of leadership at Leading BioSciences since the company’s early days in 2010. He has driven a steady increase in shareholder value by leading the company’s capital formation, operational maturity and team development, and helping to advance our lead drug candidate, LB1148, into Phase 2 clinical trials for multiple high-need indications,” said Mr. Straw. “Greg will continue to build on our founding vision to become the premier biopharmaceutical company focused on disease states caused by the mucosal barrier breakdown.”
Mr. Doyle, serving as COO and CFO, led efforts to raise over $20 million in private capital over the past six years. In addition to his financial acumen, his strategic decision making has led to mission critical discoveries in new indications for the company’s lead drug, LB1148, as well as issuance of key company patents. In addition, Mr. Doyle’s leadership has helped shape the design of numerous patient trials and build a team of experienced executives and scientific advisors to fulfill the company’s vision.
“I am honored to be at the helm of Leading BioSciences during this critical stage of growth, as we move forward in bringing much-needed treatments to patients with post-operative ileus, surgical adhesions and severe shock,” Mr. Doyle said. “My priority is to build upon our strong and productive relationships with shareholders, the investment community and health authorities, as we realize our vision of building shareholder value by delivering strong clinical data and strengthening our intellectual property estate.”
Before joining Leading BioSciences, Mr. Doyle embraced entrepreneurial and senior-level leadership roles in both public and private companies, specializing in strategic management consulting, mergers and acquisitions, new-company formation and the development of early to mid-stage companies. He has held financial evaluation and due diligence roles for dozens of M&A transactions valued at more than $3 billion. He is a former managing partner at early-stage venture capital fund, InLab Ventures, has served as division president for UBICS Corp., and held strategic management consulting roles at both A.T. Kearney and Sapient Corp. Mr. Doyle is also a serial entrepreneur, having founded and sold four different companies since 1990 and successfully raised more than $60 million in seed and Series A and B funds for his own startups.
Mr. Doyle received his Masters of Business Administration from the University of Southern California Marshall School of Business and a Bachelor of Science in finance from Brigham Young University.
About Leading BioSciences Inc.
Leading BioSciences is a clinical-stage biopharmaceutical company advancing a novel therapeutic that addresses the breakdown of the intestinal mucosal barrier — a process believed to drive a range of serious health conditions in need of effective treatment options. With a deep and pioneering scientific understanding of this emerging area of biology, Leading BioSciences has developed a patented approach that can be applied to widespread conditions, including acute shock, multiple organ failure, postoperative ileus and surgical adhesions. Phase 2 clinical trials are underway for Leading BioSciences’ investigational drug LB1148, which is supported by a robust base of positive preclinical outcomes and more than $22 million in foundational research backed by the National Institutes of Health. Visit www.leadingbiosciences.com for additional information.
SOURCE Leading BioSciences Inc.
Work experience in the biotech, pharmaceutical or semiconductor industries is desirable. Construct and execute controlled experiments (including DOE’s) to…$40 an hour
From International Programming & Systems Inc. – 23 Jun 2016 05:41:0…